Countering the 'counterattack' hypothesis.

Countering the 'counterattack' hypothesis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Countering the 'counterattack' hypothesis. Abstract Text:

Countering the 'counterattack' hypothesis. Publishing Authors By Initials

For similar eye diseases: uveal diseases: uveitis research abstracts see: eye diseases: uveal diseases: uveitis research

PUBMED ID PMID:

MEDLINE DATE:

Countering the 'counterattack' hypothesis. Journal Published:

PUBLICATION TYPE: Letter

Journal: Nature medicine

VOLUME: 7

Page Numbers: 259

Journal Abbreviation: Nat. Med.

ISSN: 1078-8956

DAY: 28

MONTH: Mar

YEAR: 2001

Countering the 'counterattack' hypothesis. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9502015

Countering the 'counterattack' hypothesis. Keywords Mesh Terms:

KEYWORDS: Uveitis

MESH TERMS: immunology

Chemical & Substance for Abstract: Countering the 'counterattack' hypothesis. Information

Substance Name: Membrane Glycoproteins

Registry Number: 0

Grant and Affiliation Information for Countering the 'counterattack' hypothesis.

AFFILIATION:

Country: United States

AGENCY: United States NCI

GRANT: Z01 BC010763-01

ACRONYM: BC

MEDLINETA: Nat Med

REFSOURCE: Nat Med. 2001 Mar;7(3):271-4

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Countering the 'counterattack' hypothesis Related Publications

• Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.
• Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways.
• Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".
• Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity.
• CD8+ T-cell memory in tumor immunology and immunotherapy.
• Cancer vaccines: progress reveals new complexities.
• Countering the 'counterattack' hypothesis.
• Creating therapeutic cancer vaccines: notes from the battlefield.
• Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen.
• Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.
• DNA and RNA-based vaccines: principles, progress and prospects.
• Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy?
• Enhancement of tumor-specific immune response with plasmid DNA replicon vectors.
• Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function.
• Hierarchy, tolerance, and dominance in the antitumor T-cell response.
• IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.
• IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.
• Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice.
• Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice.
• Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses.
• Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen.
• Natural selection of tumor variants in the generation of "tumor escape" phenotypes.
• NeuronMetrics: software for semi-automated processing of cultured neuron images.
• Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1.
• Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.
• Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL.
• The future of interleukin-2: enhancing therapeutic anticancer vaccines.
• Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen.
• Toll-like receptors in tumor immunotherapy.
• Vaccines to die for.